WallStreetZenWallStreetZen

NYSE: LLY
Eli Lilly & Co Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Eli Lilly & Co earnings were $18.4B for the trailing 12 months ending Sep 30, 2025, with 120.6% growth year over year. The latest LLY earnings report on Sep 30, 2025 announced Q3 2025 earnings of $5.6B, down 1.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, LLY reported annual earnings of $10.6B, with 102.1% growth.

LLY past earnings growth

How has LLY's earnings growth performed historically?

Company
120.56%
Industry
344.33%
Market
55.48%
LLY's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
LLY's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
LLY's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

LLY earnings history

Current Revenue
$59.4B
Current Earnings
$18.4B
Current Profit Margin
31%
LLY's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

LLY Return on Equity

Current Company
102.3%
Current Industry
118.3%
Current Market
36.2%
LLY's Return on Equity (102.3%)... subscribe to Premium to read more.
High Return on Equity Performance

LLY undefined

Current Company
19.2%
Current Industry
11.9%
LLY is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when LLY announces earnings.

LLY undefined

Current Company
30.09%
Current Industry
19.9%
LLY has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

LLY vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
LLY$24.40B$18.41B+27.21%$20.49
JNJ$39.78B$25.12B+10.06%$10.43
ABBV$12.49B$2.39B-22.48%$1.33
AZN$19.64B$9.40B+26.15%$3.04
MRK$27.65B$19.03B+10.72%$7.57
View Top General Drug Manufacturer Stocks

Eli Lilly & Co Earnings Reports & History FAQ

What were Eli Lilly & Co's earnings last quarter?

On LLY's earnings call on Invalid Date, Eli Lilly & Co (NYSE: LLY) reported Q3 2025 earnings per share (EPS) of $6.22, up 475.93% year over year. Total LLY earnings for the quarter were $5.58 billion. In the same quarter last year, Eli Lilly & Co's earnings per share (EPS) was $1.08.

If you're new to stock investing, here's how to buy Eli Lilly & Co stock.

Is Eli Lilly & Co profitable or losing money?

As of the last Eli Lilly & Co earnings report, Eli Lilly & Co is currently profitable. Eli Lilly & Co's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $18.41 billion, a 119.98% increase year over year.

What was LLY's earnings growth in the past year?

As of Eli Lilly & Co's earnings date in Invalid Date, Eli Lilly & Co's earnings has grown 120.56% year over year. This is 223.77 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 344.33%. LLY earnings in the past year totalled $18.41 billion.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.